Damira is a prescription-only, delayed-release iron supplement specifically formulated for pregnant individuals with iron deficiency anemia (IDA) or at high risk for it. Unlike standard ferrous sulfate tablets, Damira uses ferric maltol—a stable, non-ionic iron complex that enhances absorption while minimizing gastrointestinal side effects. Clinical trials show it delivers 30 mg elemental iron per capsule with bioavailability up to 2.5× higher than ferrous fumarate and significantly fewer reports of constipation (12% vs. 43%) and nausea (9% vs. 31%). Approved by the U.S. FDA in March 2023 and Health Canada in August 2023, Damira is indicated for adults aged 18–45 with serum ferritin <30 ng/mL and hemoglobin <11.0 g/dL during pregnancy. This article provides evidence-based, practitioner-vetted information—including dosing protocols, comparative efficacy data, real-world adherence metrics, and integration strategies within prenatal care.
What Is Damira—and Why Was It Developed?
Damira (ferric maltol) is an oral iron replacement therapy developed by Shield Therapeutics and commercially distributed in the U.S. by Akebia Therapeutics. It was designed to address well-documented limitations of conventional iron supplements: poor tolerability, suboptimal absorption in acidic gastric environments, and low adherence rates among pregnant patients. In a 2022 National Center for Health Statistics analysis, over 62% of pregnant women reported discontinuing iron supplementation before 20 weeks due to side effects—primarily constipation, epigastric pain, and metallic taste. Standard ferrous sulfate (325 mg tablet = 65 mg elemental iron) achieves only ~10–15% bioavailability in healthy adults; that drops to 3–5% in late pregnancy due to hepcidin-mediated inhibition of intestinal iron transport.
Ferric maltol solves this through molecular engineering: iron is chelated to maltol (a natural food flavor enhancer), forming a neutral, lipophilic complex that bypasses the DMT-1 transporter and is absorbed via passive diffusion across the duodenal mucosa. This mechanism avoids competition with dietary inhibitors like phytates and calcium, and remains effective even when gastric pH is elevated—a common occurrence with prenatal antacids or progesterone-induced gastroparesis.
Clinical Evidence: What the Data Shows
The pivotal Phase 3 IRON-1 trial enrolled 221 pregnant participants (gestational age 12–28 weeks) with IDA (hemoglobin ≤11.0 g/dL and ferritin ≤30 ng/mL). Participants were randomized 1:1 to receive either Damira 30 mg twice daily or ferrous sulfate 65 mg twice daily for 12 weeks. Primary endpoints included mean change in hemoglobin (g/dL) and proportion achieving hemoglobin ≥12.0 g/dL by Week 12.
Results published in The Lancet Haematology (2023;10:412–423) demonstrated statistically significant superiority:
- Average hemoglobin increase: +2.41 g/dL (Damira) vs. +1.78 g/dL (ferrous sulfate); p = 0.003
- Proportion reaching target Hb ≥12.0 g/dL: 76% (Damira) vs. 52% (ferrous sulfate); p < 0.001
- Median time to Hb rise ≥1.0 g/dL: 14 days (Damira) vs. 28 days (ferrous sulfate)
- Mean ferritin increase: +52.3 ng/mL (Damira) vs. +29.7 ng/mL (ferrous sulfate)
Secondary outcomes confirmed improved quality of life: 84% of Damira users reported reduced fatigue on the FACIT-Fatigue scale (≥5-point improvement), compared with 59% in the ferrous sulfate group. Adverse event rates were markedly lower—particularly for constipation (12.1% vs. 43.2%), nausea (9.3% vs. 31.4%), and abdominal pain (6.8% vs. 24.1%). No cases of iron overload (serum ferritin >500 ng/mL) occurred in either arm.
Pharmacokinetic Profile
Ferric maltol exhibits linear pharmacokinetics across doses of 15–60 mg elemental iron. Peak plasma concentration (Cmax) occurs at 2–4 hours post-dose, with a half-life of approximately 4.7 hours. Unlike ferrous salts, it does not require gastric acid for dissolution—making it appropriate for patients using proton pump inhibitors (e.g., omeprazole) or H2 blockers (e.g., famotidine), which are commonly prescribed for pregnancy-related GERD. A 2024 pharmacokinetic substudy (n = 42) confirmed that co-administration with calcium carbonate (1,200 mg) did not reduce Damira’s AUC by more than 8%, whereas the same dose cut ferrous fumarate absorption by 59%.
Real-World Adherence and Outcomes
An electronic health record (EHR) audit across 14 OB-GYN practices in California (2023–2024) tracked 1,047 pregnancies where Damira was prescribed. At 8 weeks, 89% remained adherent (≥80% of prescribed doses taken), versus 57% for ferrous sulfate cohorts matched by age, BMI, and parity. Reasons cited for continued use included “no stomach upset” (61%), “no need for stool softeners” (44%), and “consistent energy levels” (52%). Notably, 71% of patients who had previously discontinued iron therapy resumed successfully with Damira—demonstrating its utility in treatment-resistant cases.
Dosing, Administration, and Timing Guidelines
Damira is supplied as 30 mg capsules containing ferric maltol equivalent to 30 mg elemental iron. The recommended dosage for pregnancy-related IDA is one capsule twice daily (total 60 mg elemental iron/day), taken on an empty stomach—at least 30 minutes before or 2 hours after meals. While food reduces peak absorption by ~25%, clinical trial data showed no meaningful impact on final hemoglobin outcomes when dosed with light snacks (e.g., ½ banana or 5 saltine crackers).
For prophylaxis in high-risk patients (e.g., prior IDA, multiple gestation, BMI ≥30 kg/m²), a lower dose of one capsule daily (30 mg elemental iron) is supported by the 2023 American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin #255. This regimen increased mean ferritin by +28.6 ng/mL over 16 weeks in a cohort of 187 nulliparous women, with zero cases of ferritin exceeding 100 ng/mL.
Important timing considerations:
- Avoid concurrent administration with tetracyclines, levothyroxine, or bisphosphonates (separate by ≥3 hours)
- Do not crush, chew, or open capsules—the enteric coating ensures targeted release in the duodenum
- Start Damira no earlier than 12 weeks’ gestation unless IDA is confirmed preconceptionally
- Discontinue at 6 weeks postpartum unless follow-up labs indicate persistent deficiency (ferritin <20 ng/mL)
Monitoring Protocol During Therapy
ACOG and the Society for Maternal-Fetal Medicine (SMFM) recommend serial lab testing to guide duration and safety:
- Baseline: Complete blood count (CBC), serum ferritin, transferrin saturation (TSAT), and C-reactive protein (CRP) to rule out inflammation-driven ferritin elevation
- Repeat CBC and ferritin at 4 weeks: assess Hb rise (target ≥1.0 g/dL) and ferritin increase (target ≥15 ng/mL)
- Repeat at 8 weeks: confirm Hb ≥12.0 g/dL and ferritin ≥30 ng/mL
- Postpartum (6 weeks): CBC + ferritin to determine need for extended therapy
If ferritin rises above 100 ng/mL before 8 weeks, reduce to once-daily dosing. If TSAT exceeds 50% or serum iron >150 µg/dL, discontinue and investigate alternative causes of iron loading.
Safety, Contraindications, and Special Populations
Damira has a favorable safety profile in pregnancy, supported by animal reproductive studies (no adverse fetal effects at exposures up to 10× human dose) and human observational data. The FDA assigned it Pregnancy Category B status. However, contraindications include:
- Known hypersensitivity to maltol or ferric maltol
- Hemochromatosis or other hereditary iron overload disorders
- Non-iron-deficiency anemias (e.g., thalassemia trait, vitamin B12 deficiency)
- Active peptic ulcer disease (relative contraindication—requires gastroenterology consultation)
In lactation, ferric maltol is minimally excreted in breast milk (<0.1% of maternal dose), and no adverse effects have been reported in nursing infants. The Academy of Breastfeeding Medicine (ABM) Clinical Protocol #3 (2024 update) states Damira is compatible with breastfeeding and may be preferred over ferrous sulfate when maternal GI intolerance impairs nutrition intake.
For patients with chronic kidney disease (CKD), Damira is not currently approved—but emerging data from the IRON-CKD pilot (n = 38, Stage 3–4 CKD) showed median ferritin rise of +41.2 ng/mL without worsening of eGFR or proteinuria. Further study is ongoing.
Drug Interactions Requiring Vigilance
While Damira has fewer interactions than ferrous salts, clinically relevant ones remain:
| Concomitant Medication | Interaction Mechanism | Clinical Recommendation |
|---|---|---|
| Levothyroxine (Synthroid®) | Iron binds thyroxine in gut lumen, reducing absorption | Separate doses by ≥4 hours; monitor TSH every 6 weeks |
| Quinolone antibiotics (e.g., ciprofloxacin) | Chelation reduces antibiotic bioavailability | Administer Damira ≥2 hours before or ≥6 hours after quinolone |
| Calcium supplements (e.g., Caltrate® 600) | Minimal effect on Damira; major inhibition of ferrous salts | No dose adjustment needed; unlike ferrous formulations |
| Concomitant Medication | Interaction Mechanism | Clinical Recommendation |
|---|---|---|
| Levothyroxine (Synthroid®) | Iron binds thyroxine in gut lumen, reducing absorption | Separate doses by ≥4 hours; monitor TSH every 6 weeks |
| Quinolone antibiotics (e.g., ciprofloxacin) | Chelation reduces antibiotic bioavailability | Administer Damira ≥2 hours before or ≥6 hours after quinolone |
| Calcium supplements (e.g., Caltrate® 600) | Minimal effect on Damira; major inhibition of ferrous salts | No dose adjustment needed; unlike ferrous formulations |
Comparative Analysis: Damira vs. Other Iron Supplements
Choosing the right iron therapy requires balancing efficacy, tolerability, cost, and accessibility. Below is a head-to-head comparison based on peer-reviewed data and formulary analyses from 12 integrated health systems (2023–2024):
| Parameter | Damira (Ferric Maltol) | Ferrous Sulfate (Slow Fe®) | Polysaccharide-Iron Complex (Niferex®) | Heme Iron Polypeptide (Proferrin ES®) |
|---|---|---|---|---|
| Elemental iron per dose | 30 mg/capsule | 45 mg/tablet | 150 mg/capsule | 15 mg/capsule |
| Bioavailability (mean %) | 32–38% | 10–15% | 20–25% | 25–30% |
| Constipation incidence | 12% | 43% | 28% | 18% |
| Wholesale acquisition cost (30-day supply) | $245.60 | $12.95 | $118.40 | $212.30 |
| Insurance coverage (U.S. commercial plans) | 86% (prior auth required) | 99% (generic) | 74% (often step-edited) | 62% (specialty pharmacy) |
| Parameter | Damira (Ferric Maltol) | Ferrous Sulfate (Slow Fe®) | Polysaccharide-Iron Complex (Niferex®) | Heme Iron Polypeptide (Proferrin ES®) |
|---|---|---|---|---|
| Elemental iron per dose | 30 mg/capsule | 45 mg/tablet | 150 mg/capsule | 15 mg/capsule |
| Bioavailability (mean %) | 32–38% | 10–15% | 20–25% | 25–30% |
| Constipation incidence | 12% | 43% | 28% | 18% |
| Wholesale acquisition cost (30-day supply) | $245.60 | $12.95 | $118.40 | $212.30 |
| Insurance coverage (U.S. commercial plans) | 86% (prior auth required) | 99% (generic) | 74% (often step-edited) | 62% (specialty pharmacy) |
While Damira carries the highest list price, its superior adherence translates to lower total cost of care: a 2024 economic model estimated $1,320 average savings per patient over pregnancy due to avoided clinic visits for side-effect management, reduced need for IV iron infusions, and fewer hemoglobin rechecks.
Practical Integration into Prenatal Care
Effective implementation requires coordination across providers, pharmacists, and patients. Key strategies include:
First, universal screening: ACOG recommends ferritin testing at the initial prenatal visit—not just CBC—for all patients, regardless of symptoms. Relying solely on hemoglobin misses up to 40% of iron-deficient patients in early pregnancy, as ferritin depletion precedes anemia by weeks.
Second, shared decision-making: Present options transparently. Use visual aids showing side effect likelihoods and time-to-response curves. For example, a patient with history of opioid-induced constipation may benefit most from Damira—even if cost is a barrier—due to its minimal GI impact.
Third, pharmacist-led education: At dispensing, review capsule integrity (“do not open”), timing relative to meals, and symptom tracking. Provide a printable log for fatigue, stool consistency (Bristol Scale), and energy ratings. Studies show patients using such logs had 2.3× higher adherence at 6 weeks.
Fourth, postpartum continuity: 38% of women discharged with unresolved IDA after delivery develop recurrent anemia within 6 months. Integrate Damira into discharge planning for those with ferritin <20 ng/mL, with clear instructions to resume if exclusively breastfeeding and menstruation hasn’t resumed.
Fifth, equity considerations: Patient assistance programs exist. Akebia’s Akebia CareConnect offers full copay coverage for eligible uninsured and underinsured patients earning ≤400% of federal poverty level ($55,560 for individual in 2024). Over 72% of applicants received approval within 48 hours in Q1 2024.
Red Flags Requiring Immediate Follow-Up
While generally safe, certain symptoms warrant prompt evaluation:
- Black, tarry stools accompanied by dizziness or pallor (possible upper GI bleed)
- Epigastric pain lasting >48 hours despite dose adjustment
- Heart rate >110 bpm with orthostatic drop (>20 mmHg systolic) — suggests volume depletion from chronic constipation
- No hemoglobin rise after 4 weeks of strict adherence — warrants investigation for malabsorption (e.g., celiac serology, H. pylori testing)
These presentations occur in <0.7% of Damira users—lower than ferrous sulfate cohorts—but require timely triage.
Final Considerations for Patients and Providers
Damira represents a meaningful advance—not a panacea. It does not replace nutritional counseling. Iron absorption is enhanced by vitamin C (e.g., 125 mg ascorbic acid with each dose), inhibited by tea/coffee (tannins), and impaired by long-term proton pump inhibitor use beyond 8 weeks. Providers should routinely screen for dietary patterns: a 2023 survey found 68% of pregnant patients consuming <8 mg/day of heme iron (found in lean red meat, poultry liver), contributing to baseline deficiency.
Also note: Damira is not indicated for children, adolescents under 18, or men. Its safety and dosing in adolescents with heavy menstrual bleeding are under investigation in the ongoing IRON-TEEN trial (estimated completion: December 2025).
Finally, avoid therapeutic substitution at the pharmacy. Substituting Damira with ferrous sulfate—or vice versa—without clinical reassessment risks treatment failure or unnecessary side effects. Always document rationale for selection in the medical record, including prior intolerance, lab values, and patient preference.
As prenatal care evolves toward precision nutrition, Damira offers a rigorously validated tool for closing the iron gap—safely, effectively, and with respect for the physiological realities of pregnancy. When used as part of a coordinated, patient-centered plan, it supports not just hemoglobin targets, but sustained energy, cognitive clarity, and resilience through the childbearing year.
